BridgeBio partners with biomanufacturer Resilience to produce early-stage AAV gene therapies
BridgeBio has tapped biomanufacturing company National Resilience to produce two of its early-phase adeno-associated virus (AAV) gene therapies in a partnership designed to run beyond clinical trials.
Resilience is tasked to manufacture AAV5 gene therapy BBP-631 for congenital adrenal hyperplasia and AAV9 gene therapy BBP-812 for Canavan disease. BBP-631 is in a 25-patient Phase I/II trial, with early data expected before the end of the year. Meanwhile, BBP-812 is in an 18-patient Phase I/II study, with results likely to be unveiled next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
